Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer

Roche announced today that the European Commission has approved the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)-activating mutations.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news